Navigation Links
Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
Date:3/5/2010
SOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today at the 2010 American Society of Clinical Oncology's Genitourinary Cancers Symposium in San Francisco, CA.
The final data showed that picoplatin, in combination with docetaxel and prednisone, the current standard of care for CRPC, produced a clinically meaningful benefit in patients as measured by overall survival, progression-fr
'/>"/>
| SOURCE Poniard Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |
Related medicine news :
1. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
2. Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August
3. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
4. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
5. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
6. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. Poniard Pharmaceuticals Receives Going Concern Qualification
9. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
10. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
11. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
(Date:5/22/2013)... features Toppik and Bosley hair fibers, two hair loss concealer ... balding hair. Hair loss treatments can be a lengthy process. ... this waiting period, one can use these hair loss concealers. ... transplant surgery in general. , Bosley and Toppik Hair ... to eliminate the appearance of balding and thinning hair. It ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Beginning Aug. ... in the Conrad Foundation’s Spirit of Innovation Challenge ... technical plan competition, free and open to students ages ... The Spirit of Innovation Challenge celebrates the life and ... walk on the Moon. The program challenges teens to ...
(Date:5/22/2013)... MD (PRWEB) May 22, 2013 According ... is an autoimmune disorder effecting up to 3 million ... causing damage to the small intestine and mal-absorption of ... such as diarrhea, constipation, weight loss and vitamin deficiency, ... diet. While there are many gluten-free foods that celiac ...
(Date:5/22/2013)... Toronto, May 22 2013 - Research presented today ... reactions in rats similar to those produced by ... results, presented by addiction expert Francesco Leri, Associate ... the University of Guelph, suggest food addiction could ... epidemic. These results were presented at the ...
(Date:5/22/2013)... (HealthDay News) -- Use of the antidepressant Lexapro ... heart condition, a new study finds. ... stress-induced myocardial ischemia." Although people with this condition ... is not receiving adequate blood supply, according to ... Durham, N.C. However, the researchers found that ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2Health News:Conrad Foundation Announces 2013-2014 Spirit of Innovation Challenge Launch Date 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 3Health News:Addiction to unhealthy foods could help explain the global obesity epidemic 2Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 2Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 3[0] TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers[0] Conrad Foundation Announces 2013-2014 Spirit of Innovation Challenge Launch Date[0] During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula[0] Addiction to unhealthy foods could help explain the global obesity epidemic[0] Antidepressants May Be Helpful for Some Heart Patients: Study
... million children under the age of five and 1.7 ... sanitation, an international conference was told Saturday. // , ... utmost importance, and if we have to ensure gender ... problems need immediate attention," said Bindeshwar Pathak, founder, Sulabh ...
... discovery of neural stem cells and their potential for someday ... recent research identified “cancer stem cells,” a small population of ... a malignant brain tumor. Theoretically, if these mother cells can ... itself. On the other hand, if these cells are not ...
... A in a middle school in south China's Guangxi Zhuang ... said Friday//. ,All the students have been identified as ... suffering from symptoms of hepatitis A and 33 others are ... head of the Guangxi centre for disease control and prevention. ...
... Children’s Hospital Boston report a new and efficient strategy, ... that can be transplanted// without the risk of rejection ... system. ,Though done in mice, the work establishes ... of customized embryonic stem cells that are genetically matched ...
... under-report patient safety incidents, particularly those resulting in harm, ... authors suggest that the current system, which relies on ... is to gather accurate information on the extent of ... safety incidents are common in hospitals, and many of ...
... Scientific, technological and medical advances made in the past ... and more effective treatment options/// and better outcomes for ... the article, Shlomo Melmed, M.D., senior vice president for ... Research Institute at Cedars-Sinai, provides an update on medical ...
Cached Medicine News:Health News:Poor Sanitation Causes 3.1 Million Child Deaths In Asia 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 3Health News:Researchers Create Genetically-Matched Embryonic Stem Cells for Transplantation 2Health News:Researchers Create Genetically-Matched Embryonic Stem Cells for Transplantation 3Health News:Hospitals Miss Most Patient Safety Incidents 2Health News:Options Improving for Patients With Acromegaly and Gigantism 2Health News:Options Improving for Patients With Acromegaly and Gigantism 3Poor Sanitation Causes 3.1 Million Child Deaths In AsiaGenes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment IdentifiedMore Than 100 Students Affected by Hepatitis in ChinaResearchers Create Genetically-Matched Embryonic Stem Cells for TransplantationHospitals Miss Most Patient Safety IncidentsOptions Improving for Patients With Acromegaly and Gigantism
(Date:5/22/2013)... WORCESTER, Mass. and TORONTO ... www.generex.com ) (OTCBB: GNBT) today announced three presentations demonstrating ... developed by its wholly-owned subsidiary, Antigen Express, Inc. ( ... annual meeting of the American Society of Clinical Oncology ... from May 31 through June 4, 2013. ...
(Date:5/22/2013)... , 22. Mai 2013 Grifols, ... in Barcelona , Spanien, ... dass eine höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer ... mit Alpha1-Antitrypsinmangel (AAT) auf ein Niveau anhebt, ... bezeichneten Bereichs liegt. ATT-Mangel ist eine lebensbedrohliche, ...
(Date:5/22/2013)... TORONTO , May 22, 2013 Medifocus, Inc. ... John Mon , Chief Operating Officer, will present at ... 30, 2013 in New York City ... presentation is scheduled to begin at 4:00 p.m. EDT and ... webcast, go to: http://wsw.com/webcast/marcum/mfs.v/ For more ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3[0] Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine[0] Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt[0] Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference
... Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... acquire Proteolix, Inc., a privately held biopharmaceutical company ... target the proteasome for the treatment of hematological ... carfilzomib, is a proteasome inhibitor currently in multiple ...
... , EXTON, Pa., Oct. 9 Kensey Nash ... release its earnings results for its first quarter ended September ... 22, 2009. , Joe Kaufmann, President and CEO, ... Thursday, October 22, 2009 at 9:00 A.M. Eastern Time. ...
Cached Medicine Technology:Onyx Pharmaceuticals to Acquire Proteolix, Inc. 2Onyx Pharmaceuticals to Acquire Proteolix, Inc. 3Onyx Pharmaceuticals to Acquire Proteolix, Inc. 4Onyx Pharmaceuticals to Acquire Proteolix, Inc. 5Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference 2... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |